"Thymoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin's disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (From Stedman, 25th ed)
- Carcinoma, Thymic
- Carcinomas, Thymic
- Thymic Carcinoma
- Thymic Carcinomas
Below are MeSH descriptors whose meaning is more general than "Thymoma".
Below are MeSH descriptors whose meaning is more specific than "Thymoma".
This graph shows the total number of publications written about "Thymoma" by people in this website by year, and whether "Thymoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Thymoma" by people in Profiles.
Jackson MW, Palma DA, Camidge DR, Jones BL, Robin TP, Sher DJ, Koshy M, Kavanagh BD, Gaspar LE, Rusthoven CG. The Impact of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma. J Thorac Oncol. 2017 04; 12(4):734-744.
Park DB, Dobson JV, Losek JD. All that wheezes is not asthma: cognitive bias in pediatric emergency medical decision making. Pediatr Emerg Care. 2014 Feb; 30(2):104-7.
Nguyen CL, Salem ML, Rubinstein MP, Demcheva M, Vournakis JN, Cole DJ, Gillanders WE. Mechanisms of enhanced antigen-specific T cell response following vaccination with a novel peptide-based cancer vaccine and systemic interleukin-2 (IL-2). Vaccine. 2003 Jun 02; 21(19-20):2318-28.
Nguyen CL, Bui JT, Demcheva M, Vournakis JN, Cole DJ, Gillanders WE. Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response. J Immunother. 2001 Sep-Oct; 24(5):420-9.
Maitre N, Brown JM, Demcheva M, Kelley JR, Lockett MA, Vournakis J, Cole DJ. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination. Clin Cancer Res. 1999 May; 5(5):1173-82.
Skeie GO, Pandey JP, Aarli JA, Gilhus NE. TNFA and TNFB polymorphisms in myasthenia gravis. Arch Neurol. 1999 Apr; 56(4):457-61.
Kulling D, Reed CE, Verne GN, Cotton PB, Tarnasky PR. Intestinal pseudo-obstruction as a paraneoplastic manifestation of malignant thymoma. Am J Gastroenterol. 1997 Sep; 92(9):1564-6.
Skeie GO, Pandey JP, Aarli JA, Gilhus NE. Autoimmunity to ryanodine receptor and titin in myasthenia gravis is associated with GM allotypes. Autoimmunity. 1997; 26(2):111-6.
Gilhus NE, Pandey JP, Gaarder PI, Aarli JA. Immunoglobulin allotypes in myasthenia gravis patients with a thymoma. J Autoimmun. 1990 Jun; 3(3):299-305.
Kraft AS, Anderson WB, Cooper HL, Sando JJ. Decrease in cytosolic calcium/phospholipid-dependent protein kinase activity following phorbol ester treatment of EL4 thymoma cells. J Biol Chem. 1982 Nov 25; 257(22):13193-6.